Gilead Sciences Company Updates |

Company Updates

  • People who are most vulnerable to #HIV, including transgender women, often face difficult barriers to accessing prevention and care, including stigma and discrimination. Help replace stigma with science by spreading facts about HIV. Watch this video with Blossom from the Los Angeles LGBT Center and talk to a healthcare provider for more information on your sexual health: #SpreadFactsNotFear

  • The increasing availability of effective #HIV treatments within low and middle-income countries has produced encouraging signs of progress, yet there is more work to be done to fight the epidemic. Our VP of Access Operations and Emerging Markets, Papa Salif Sow, expands on this global-scale effort to improve access in this month’s issue of New Scientist:

    The global treatment plan helping to control the HIV epidemic

    ADVERTISING FEATURE The impact of HIV in Africa in the 1990s and 2000s was profound. "It was a horrendous time," says Kenly Sikwese, who has lived in Zambia for most of his life. One report found that, in 1999 alone, 5.4 million people were infected and 2.8 million died.

  • People living with HIV can now live longer, fuller lives thanks to a series of biomedical breakthroughs and the dedication of thousands of researchers around the world. Learn more about 30 years of progress in HIV treatment from our Medical Director, Peter Borg, in the most recent issue of New Scientist:

    How clever biochemistry is tackling HIV

    ADVERTISING FEATURE IN 1981, doctors in the US became aware of a strange phenomenon. An unusual number of healthy young men in Los Angeles and other cities were falling ill and dying from rare infections and cancers. Their symptoms suggested that something was weakening their immune systems, leaving them vulnerable to diseases they would normally fend off.

  • More than 12,000 people in Alabama were living with HIV in 2014. Douglas Brooks, our Senior Director for Community Engagement, and Nic Carlisle of the Southern AIDS Coalition highlight a new partnership with the Southern HIV/AIDS Strategy Initiative at Duke University as part of the Gilead COMPASS Initiative™ Corporate Giving Program which aims to combat the HIV/AIDS epidemic in Birmingham, AL and across the Southern U.S. Read more at

    Ending the HIV/AIDS epidemic means focusing on Birmingham

    By Nic Carlisle, Executive Director, Southern AIDS Coalition; a nd Douglas M. Brooks, MSW, Senior Director, Public Affairs, Gilead and former Director of the Office of National AIDS Policy under the Obama Administration HIV and AIDS no longer receive the attention they did during the 1980s and 1990s and, because of that, too many people believe it's a thing of the past.

  • We at Gilead Sciences support our colleagues at Kite Pharma and their dedication to driving cancer research that has the potential to improve the lives of people living with the disease around the world. #WorldCancerDay

  • CAR T cell immunotherapy named the Advance of the Year in annual ASCO report. We’re proud to play a role in advancing cell therapy:

  • We’re proud to join more than 500 organizations in support of the U=U Consensus Statement. Learn more about the U=U campaign and the full Consensus Statement:

  • Throughout 2018 we will be sharing a quick glimpse into our working lives here at Gilead. Meet Lauryn from the Regulatory Affairs team in Foster City . #gileadlife

  • Gilead's subsidiary Kite announces clinical collaboration with Pfizer to evaluate investigational treatment combination in large B-cell lymphoma. Find out more:

  • Throughout 2018 we will be sharing a quick glimpse into our working lives here at Gilead. Please meet Ligia from the Biometrics team in Foster City. #gileadlife

Work at Gilead Sciences? Share Your Experiences

Gilead Sciences
  • Star
  • Star
  • Star
  • Star
  • Star
Click to Rate